Prognostic value of intra-tumoral CD8+/FoxP3+ lymphocyte ratio in patients with resected colorectal cancer liver metastasis by Sideras, K. (Kostandinos) et al.
68 © 2018 Wiley Periodicals, Inc. wileyonlinelibrary.com/journal/jso J Surg Oncol. 2018;118:68–76.
Received: 16 February 2018 | Accepted: 17 April 2018
DOI: 10.1002/jso.25091
RESEARCH ARTICLE
Prognostic value of intra-tumoral CD8+/FoxP3+ lymphocyte
ratio in patients with resected colorectal cancer liver
metastasis
Kostandinos Sideras MD, PhD1 | Boris Galjart2 | Angela Vasaturo PhD3 |
Alexander Pedroza-Gonzalez PhD1 | Katharina Biermann MD, PhD4 |
Shanta Mancham1 | Alex L. Nigg4 | Bettina E. Hansen PhD1 |
Hans A. Stoop PhD4 | Guoying Zhou MD1 | Cornelis Verhoef MD, PhD2 |
Stefan Sleijfer MD, PhD5 | Dave Sprengers MD, PhD1 | Jaap Kwekkeboom PhD1 |
Marco J. Bruno MD, PhD1
1 Erasmus MC-University Medical Center,
Department of Gastroenterology and
Hepatology, Rotterdam, The Netherlands
2Department of Surgical Oncology, Erasmus
MC-University Medical Center, Erasmus MC
Cancer Institute, Rotterdam, The Netherlands
3Department of Tumor Immunology, Radboud
University Medical Center, Nijmegen, The
Netherlands
4Department of Pathology, Erasmus MC-
University Medical Center, Rotterdam, The
Netherlands
5Department of Medical Oncology, Erasmus
MC-University Medical Center, Erasmus MC
Cancer Institute, Rotterdam, The Netherlands
Correspondence
Marco J. Bruno, Department of
Gastroenterology and Hepatology, Erasmus
University Medical Center, H-358's
Gravendijkwal 230, 3015 CE Rotterdam, The
Netherlands.
Email: m.bruno@erasmusmc.nl
Background andObjectives:Patientswith isolated colorectal-cancer-liver-metastases
(CRCLM) frequently undergo metastatectomy. Tumor-infiltrating-lymphocytes (TILs)
have prognostic potential in the setting of primary colorectal cancer, however, their
role inCRCLM is less studied.Weaimed to study the spatial distribution andprognostic
role of tumor-infiltrating CD8+ cytotoxic T-cells and FoxP3+ regulatory T-cells at the
metastatic site of CRCLM patients.
Methods: TILs were isolated from freshmetastatic tissues of 47 patients with CRCLM.
Archived paraffin-embedded tissue, from the same patients, was retrieved. CD8+ and
FoxP3+ cells, both in the intra-tumoral and the peri-tumoral compartments, were
measured by immunohistochemistry on full tissue sections. Proportions of cytotoxic
T-cells (CD8+) and regulatory T-cells (CD4+CD25+FoxP3+), within CD45+TILs, were
measured by flow-cytometry.
Results: By immunohistochemistry, individual densities of intra-tumoral or
peri-tumoral CD8+ and FoxP3+ cells were not prognostic of survival. However, the
intra-tumoral, but not the peri-tumoral, CD8+/FoxP3+ ratio was an independent
predictor of survival (HR 0.43, 95%CI 0.19-0.95, P = 0.032). By flow cytometry, the
intra-tumoral CD8+/regulatory T-cell ratio was also an independent predictor of
survival (HR 0.45, 95%CI 0.20-0.99, P = 0.044).
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited and is not used for commercial purposes.
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Conclusions: The ratio of cytotoxic (CD8+) to regulatory (FoxP3+) T-cells, in the intra-
tumoral compartment, but not in the peri-tumoral compartment, can predict survival
after resection of CRCLM.
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1 | INTRODUCTION
Colorectal cancer is a leading cause of cancer death.1 It is now standard
for limited colorectal-cancer-liver metastases (CRCLM) to be consid-
ered for resection.2 While clinical characteristics, such as the clinical-
risk score (CRS),3 or the resection margin status,4 can prognosticate
patients, the prognostication is far from ideal.
The immune system plays an important role in cancer surveillance
and elimination.5 Tumor infiltrating lymphocytes (TILs) have emerged
as potential biomarkers in various cancers.6 In primary colorectal
cancer TILs represent a robust prognostic biomarker that is superior to
clinicopathologic characteristics7,8 with higher number of TILs
associated with improved survival.9–11 Naturally, the effect of TILs
on prognosis has subsequently been studied in the setting of resected
CRCLM. Kito et al12 showed that the presence of CD8+ TILs in CRCLM
was associatedwith longer tumor doubling times, whileWagner et al13
showed that TILs isolated from freshly resected CRCLM tumors, and
analyzed by flow cytometry, were equally abundant, although more
activated, than lymphocytes from the surrounding normal liver tissue.
Moreover, at least four studies have directly related the numbers of
TILs in CRCLM to patient prognosis.14–17 Halama et al16 and Katz
et al15 showed that TILs present at the invasive margin or in the
intratumoral compartment of metastatic CRC lesions, respectively, are
associated with improved survival, while Lee et al17 and Nakagawa
et al14 showed that only numbers of FoxP3+ regulatory T cells at the
metastatic site relate to prognosis.
However, TILs are heterogeneously defined in the literature and
different T-cell subsets have opposite effects.18While cytotoxic CD8+
T-lymphocytes have antitumor properties, CD4+CD25+FoxP3+ T-cells,
representing T-regulatory cells (Tregs), have immunosuppressive and
tumor-supporting properties.19 Another source of heterogeneity is the
histologic distribution of TILs at the tumor site. Themajority of TILs are
concentrated in the peri-tumoral area and only a minority penetrates
to the tumor tissue itself. It is unclear what the relative significance of
these TIL cell populations is.
The aim of this study was to examine the composition and spatial
distribution of TILs in CRCLM in relation to prognosis. We focused on
the role of CD8+ T-cells and Tregs. We determined the spatial
distribution of TILs by using immunohistochemistry on full tissue slides
and quantified lymphocytic populations both in the peri-tumoral and
intra-tumoral areas separately.We hypothesized that TIL infiltration in
the intra-tumoral area will be more prognostic than the peri-tumoral
area and that the ratio of immune effector (CD8+) to immune
suppressive (Tregs) T-cells will be more prognostic than the density of
each individual cell type alone. In addition, we used flow-cytometry on
TILs freshly isolated from tumor tissues and compared the results
obtained.
2 | MATERIALS AND METHODS
2.1 | Patient cohort and tissue samples
A total of 47 patients, who underwent resection for CRCLM
between September 2009 and November 2011, were enrolled.
Fresh liver tumor tissue was used to isolate TILs. Formalin fixed
paraffin-embedded tissue, from these same patients, was retrieved
from the archive. Baseline characteristics and follow-up informa-
tion were retrospectively collected from the electronic record. The
Clinical Risk Score was calculated according to Fong et al.3 Patients
were included only when no chemotherapy was given for at least
3 months prior to the metastatectomy. The study protocol
conforms to the ethical guidelines of the 1975 Declaration of
Helsinki and was approved by the Medical Ethical Committee of
Erasmus MC.
2.2 | Immunohistochemistry
Four micrometre thick sections were cut and mounted on Superfrost
PlusTM slides. For the stainings a Ventana Benchmark Ultra
automated staining system (Ventana Medical System, Tuscon, AZ)
was used, in a clinical laboratory setting. For CD8 the sectioned
specimens were processed for 16min antigen retrieval using Cell
Conditioning Solution (CC1 Ventana Ref.: 950-124). After 32min
incubation with the primary antibody (clone SP-57, Ventana Ref.: 950-
124, ready to use) at 36°C, followed by amplification with Optiview
amplification kit (Ventana ref.:760-099), detection and visualization
was performed with OptiView Universal DAB detection kit (Ventana
Ref.: 760-700). The sections were counterstained with hematoxylin II
(Ventana Ref.: 790-2208). For Fox-P3 the same protocol was applied
with the exception the sectioned specimens were processed for
64min antigen retrieval, the primary antibody (clone 236A/E7,
e-bioscience) dilution was 1:100, and amplification was performed
with the Ultraview amplification kit (Ventana ref.:760-080). Represen-
tative stainings are seen in Figure 1.
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2.3 | Evaluation of immunohistochemistry staining
Stained slides were scanned using NanoZoomer 2.0HT (Hamamatsu
Photonic, Shizuoka, Japan) at 40×. Automated digital image analysis
was performed using the Visiopharm Integrator System (version
4.2.2.0, Visiopharm, Hoersholm, Denmark). For the intra-tumoral areas
several (4-6) randomly chosen large circular areas were analyzed
(Figure 2). Necrotic areas where viable cells were virtually absent were
excluded. In many cases the total evaluated intra-tumoral area
represented the majority of the tumor section. For the peri-tumoral
areas, four representative circular areas with a diameter of 0.54mm
(area = 1 high-power field), at the interphase between tumor and
surrounding tissue, were analyzed (Figure 2). The definition of the peri-
tumoral area is similar to Halama et al.16 CD8+ and FoxP3+ cell
densities were measured as cells/mm2. All cases were visually
reviewed to ensure accuracy.
2.4 | TIL isolation and flow-cytometry
Single cell TILs were isolated via tissue digestion as previously
described.20,21 Mononuclear cells were analyzed using the following
anti-human antibodies: PerCP-labeled anti-CD8 (SK-1) and
APC-H7-labeled anti-CD4 (SK3) from BD Biosciences; APC-labeled
anti-FoxP3 (PCH101), PeCy7-labeled anti-CD3 (UCTH1), eFluor®
450-labeled anti-CD45 (HI30), and PE-labeled anti-CD25 (BC96) from
e-bioscience. The gating strategy has been previously described.20
Numbers of CD8+ TILs were defined as the proportion of CD8+ cells
within live CD45+ cells, while numbers of T-regulatory cells were
defined as the proportion of CD4+ CD25+ FoxP3+ cells within live
CD45+ cells. The gating strategy can be seen in Supplementary
Figure S1. More detailed information on TIL isolation and flow-
cytometry analysis can be found in the supplementary information.
2.5 | Statistical analysis
All analyses were performed in duplicate. Cancer-specific survival
and recurrence-free survival were calculated from the date of
metastatectomy to the date of event (death from cancer or
recurrence of cancer, respectively). Survival curves were estimated
by the Kaplan-Meier method. Differences between survival curves
were evaluated by the log-rank test. In case of no event patients
were censored at the date of last follow-up. The median density or
median proportion values of TIL populations were used to
discriminate high vresus low groups in both immunohistochemistry
and flow-cytometry. For multivariate analysis, the Cox proportional
Hazard regression analysis was used with both the ENTER method
and by backwards variable selection. Patients with missing values for
the co-variates of interest were excluded from the statistical
analysis. The associations between clinicopathologic parameters
and TIL subpopulations were examined using the χ2 tests or the T-
test as appropriate. Sensitivity analysis was performed by excluding
the three patients who underwent a second metastatectomy as well
FIGURE 1 Representative CD8 and FoxP3 immunohistochemical stains. A, Intra-tumoral and (B) peri-tumoral CD8+ cells in CRCLM. C,
CD8+ cells in positive control tonsil tissue. D, Intra-tumoral and (E) peri-tumoral FoxP3+ cells in CRCLM. F, FoxP3+ positive cells in positive
control tonsil tissue.
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as excluding the two patients who had a CEA>200 ng/mL. The
statistical analysis was performed using the SPSS© 21 software.
3 | RESULTS
3.1 | Patients and clinicopathologic characteristics
Median time to recurrence was 13.1 months and median survival
was 50.9 months. Cancer recurrence occurred in 37/47 patients
while 28/47 patients died from colorectal cancer. Baseline
characteristics are seen in Table 1. In univariate analysis only a
positive lymph-node status and a high pre-operative CEA value were
associated with cancer survival (Table 2A), while only the pre-
operative CEA value was associated with cancer recurrence (data not
shown).
3.2 | CD8+ and FoxP3+ immunohistochemical
distribution
The majority of TILs were located in the peri-tumoral areas (Figure 1
and Figure 2). The median intra-tumoral CD8+ and FoxP3+ TIL
densities were 58.6/mm2 (range 8.8-795) and 26.4/mm2 (range
0.44-255), respectively. The median peri-tumoral CD8+ and FoxP3+
TIL densities were 883/mm2 (range 409-1731) and 127/mm2 (range
8.4-525), respectively.
3.3 | Prognostic value of intra-tumoral and
peri-tumoral TILs by immunohistochemistry
Median values were used for cutoffs. Table 2B shows the
univariate analysis for the TIL populations in the intra-tumoral
and peri-tumoral areas, while Figure 3 shows the respective
Kaplan-Meier curves. Neither intra-tumoral nor peri-tumoral
CD8+ or FoxP3+ TIL densities did, individually, predict
colorectal-cancer survival. An a priori hypothesis was that the
ratio of CD8+ to FoxP3+ TILs would be a better prognosticator
than the individual TIL sub-populations. With a median cutoff of
2.42, a high intra-tumoral CD8+/FoxP3+ TIL ratio was predictive
of improved colorectal cancer survival (HR 0.43, 95%CI 0.19-
0.95, P = 0.032). On the other hand, the peri-tumoral CD8+/
FoxP3+ TIL ratio was not predictive of colorectal cancer survival.
None of the TIL parameters were predictive of colorectal cancer
recurrence.
3.4 | Prognostic value of TILs by flow-cytometry
Flow-cytometry on freshly isolated TILs, representing the intra-
tumoral compartment, was used to validate the immunohistochemi-
cal findings. Median values were used for cutoffs. While CD8+ TILs
were not predictive of colorectal cancer survival, high percentages of
Tregs within CD45+ leukocytes were associated with worse
colorectal cancer survival (HR 2.61, 95%CI 1.17-5.83, P = 0.016).
In addition, a high CD8+/Treg TIL ratio (median cutoff of 7) was
associated with improved colorectal-cancer survival (HR 0.45, 95%
CI 0.20-0.99, P = 0.044). Figure 3 shows the representative Kaplan-
Meier curves. TIL measurement by flow-cytometry was not
predictive of recurrence.
FIGURE 2 Representative example of areas used for analysis of
CD8+ and FoxP3+ cell densities. A, Photograph of full slide. B,
Zoom-in on red square of image (A). Blue circles represent intra-
tumoral areas used for analysis. Green circles represent peri-
tumoral areas used for analysis. The green circles have a diameter
of 0.54 mm (area of 0.23 mm2 or 1 HPF). Note that the areas
used for peri-tumoral analysis are centered on the middle of the
peri-tumoral infiltrate. Red arrows indicate the peri-tumoral
infiltrate.
TABLE 1 Baseline characteristics
Baseline characteristics N = 47 (% or range)
Age (median) 63.8 (35.2-84.7)
Gender (male/female) 31 (66.0)/16 (34.0)
Clinical risk score
Primary cancer lymph node status positive 27 (57.4)
Time from primary to CRCLM <12 months 17 (36.2)
Largest metastatectomy tumor size >5 cm 11 (23.4)
>1 metastatic lesion 30 (63.8)
CEA >200 ng/mL 2 (4.7)
Margin status positive (R1) 8 (17.0)
Recurrence 37 (78.7)
Cancer specific death 28 (59.6)
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3.5 | Multivariate analysis
Multivariate analysis included all known clinicopathologic character-
istics and TIL ratios predictive of survival. Both the intra-tumoral
CD8+/FoxP3+ TIL ratio obtained by immunohistochemistry (Table 3)
and the CD8+/Treg TIL ratio obtained by flow-cytometry (Table 4)
were independent predictors of colorectal cancer survival. From the
clinicopathologic characteristics only lymph node status of the primary
tumor and pre-operative CEA values were independent predictors of
survival (Tables 3 and 4).
3.6 | Sensitivity analysis
Excluding the three patients who underwent a second curative
intent metastatectomy, as well as excluding the two patients with a
pre-operative CEA value at or above 200 ng/mL, led to no
significant differences in the multivariate analysis. The intra-
tumoral CD8+/Treg TIL ratio remained an independent predictor of
colorectal cancer survival. We also repeated the multivariate
analysis using backward variable selection. We found that the
intra-tumoral CD8+/FoxP3+ TIL ratio, obtained by immunohis-
tochemistry, remained an independent predictor colorectal cancer
survival (HR 0.40, 95%CI 0.17-0.95, P = 0.037), while the CD8+/
Treg TIL ratio obtained by flow-cytometry showed a trend towards
such independence (HR 0.46, 95%CI 0.19-1.12, P = 0.087). Finally,
we analyzed for any possible effect that chemotherapy given prior
to metastatectomy, may have had on TIL populations. In
Supplementary Figure S2 we show that prior chemotherapy, given
at least 3 months prior to metastatectomy (range 3-36 months) had
no effect on TIL populations measured either by immunohis-
tochemistry (a-d) or by flow cytometry (e-f).
4 | DISCUSSION
We show that the intra-tumoral ratio, but not the peri-tumoral ratio, of
effector T-cells (CD8+ cells) to immune inhibitory T-cells (FoxP3+
T-cells), measured by immunohistochemistry, is a predictor of cancer
survival in the setting of resected CRCLM. In contrast, intra-tumoral
CD8+ T-cells or FoxP3+ T-cells, individually, could not predict survival.
In addition, we show that measuring the same ratio of effector T-cells
(CD8+ cells) to immune inhibitory T-cells (Tregs) by flow-cytometry,
using freshly isolated TILs, can also predict cancer survival following
CRCLM resection.
This observation is consistent with the hypothesis that the
quality matters more than the quantity of the immune infiltrate.22
Specifically, ratios of effector to regulatory immune cells may
provide a more comprehensive view of what occurs in the tumor
microenvironment. In fact, a large meta-analysis of TIL phenotyping,
including 33 studies and nearly 10 000 patients, showed that
lymphocyte ratios and specifically the CD8/FoxP3 ratio, have more
prognostic potential than individual lymphocytic subtype densities.23
In addition, while a lymphocytic infiltrate may be attracted to the
margin of the tumor it does not mean that it will lead to tumor
disruption. CRCLM may prevent the migration of TILs into the tumor
itself, which may be due to chemokine to chemokine receptor
TABLE 2 Univariate Cox proportional Hazard regression analysis of patients’ survival
Variables HR 95%CI P-value
(A) Baseline characteristics
Age (per decade increase) 0.99 0.71-1.38 0.957
Gender (male vs female) 0.78 0.35-1.64 0.485
Primary cancer lymph node status positive 2.58 1.15-5.78 0.022
Time from primary to CRCLM <12 months 1.01 0.47-2.16 0.977
Largest metastatectomy tumor size >5 cm 1.17 0.50-2.75 0.730
>1 metastatic lesion 1.07 0.49-2.31 0.872
CEA >200 ng/mL 6.88 1.82-25.98 0.004
CRS (0-5) 1.25 0.88-1.77 0.221
Margin Margin status (R0 vs R1) 1.46 0.59-3.61 0.412
(B) TIL parametersa
CD8 peri-tumoral area 0.80 0.38-1.75 0.571
FoxP3 peri-tumoral area 1.08 0.50-2.29 0.852
CD8/FoxP3 peri-tumoral area 0.91 0.43-1.95 0.813
CD8 intra-tumoral area 0.58 0.27-1.27 0.169
FoxP3 intra-tumoral area 0.83 0.39-1.77 0.622
CD8/FoxP3 intra-tumoral area 0.43 0.19-0.95 0.038
aMedian values were used as cutoffs.
Bold values signify statistically significant parameters.
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mismatch, aberrant microvasculature, cytokine production, a
mechanical barrier, or immunosuppression itself.24
Four prior studies have attempted to examine the prognostic role
of TILs in CRCLM. Halama et al16 examined TIL infiltration on full slides
in a 500 μm area from the tumor edge. The area was termed the
“invasive margin”, which may be similar to what we defined as peri-
tumoral area in our study. In 33 resected patients (68 additional
patients had unresectable disease) Halama et al16 found that high “TIL
density” was associated with improved survival. Differences with our
study are that Halama et al16 studied only the area of the peri-tumoral
infiltrate (the invasive margin) and “TIL density” was defined as a
combination of CD3, CD8, and granzyme B staining.
A study by Katz et al15 used three 0.6 mm TMA cores per
patient, taken from 188 patients with CRCLM. They showed that a
high CD8/FoxP3 ratio (or a low FoxP3/CD8 ratio as defined in their
study) predicts improved survival following CRCLM resection, a
finding that is in agreement with our immunohistochemical findings.
The fact that they used only three small TMA cores means they
examined a much smaller area of tumor than in our study but
reached a similar conclusion nonetheless. The TMA cores from the
Katz et al15 study likely correspond to the intra-tumoral areas in our
study, which may explaining the similarity in our results. Katz et al15
however, did not examine the peri-tumoral area, given the general
difficulty of TMA cores to reliably capture the histologic complexity
of that narrow area.
A study by Lee et al17 examined TMAs consisting of 5 mm cores
taken from 79 patients with synchronous only CRCLM. TILs in the liver
metastasis were compared to TILs in the corresponding primary
tumors. While in univariate analysis a higher FoxP3+ density at the
metastatic site corresponded to better outcome, in multivariate
analysis only CD45RO+ cell density at the primary site was prognostic
of survival. Our study did not examine the relative role of TILs in the
FIGURE 3 Kaplan Meier curves of potential TIL biomarkers. CD8+ and FoxP3+ cell densities by immunohistochemistry were measured
as numbers of cells/mm2 tissue. Cytotoxic T-cells and Treg proportions by flow-cytometry were measured as proportions of CD8+ or
CD4 + CD25 + FoxP3+ cells within CD45+ leukocytes respectively. Median numbers were used for all the cutoff values.
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corresponding primary sites thus is difficult to compare our findings to
the study by Lee et al17 More importantly however, it is unclear where
the TMA cores were taken from and no CD8/FoxP3 ratio was
reported.
Finally, a more recent study by Nakagawa et al14 examined
full slides from 162 patients with CRCLM. Both intra-tumoral and
peri-tumoral areas were examined according to the authors. High
peri-tumoral FoxP3 density was found to be associated with
improved survival, while peri-tumoral CD8 and intra-tumoral CD8
and FoxP3 densities did not predict survival individually. Ratios of
CD8 to FoxP3 densities were not examined. In addition, no
definition of what constituted peri-tumoral or intra-tumoral areas
was given.
It is clear from the above studies that significant heterogeneity
in study design and terminology exists. In fact, differences in
methodology, rather than differences in biology, have been
hypothesized before to account in differences amongst study
observations.23 In the case of CRCLM, only two prior studies14,16
have used full slides, allowing for comparison of intra-tumoral and
peri-tumoral TIL populations and none of these studies commented
on the possible significance of the CD8/FoxP3 ratio, which we show
to be the strongest prognostic marker. On the other hand, the study
by Katz et al15 which found the CD8/FoxP3 ratio to be prognostic of
survival, concordant to our immunohistochemical findings, did not
examine the peri-tumoral infiltrate.15 While we validate the findings
of Katz et al15 we show, in addition, that it is indeed the intra-
tumoral infiltrate that matters the most.
A novelty of our study is the validation of our immunohisto-
chemical observations by flow-cytometry on prospectively collected
TILs. There are however several differences in determining TIL
densities by immunohistochemistry versus flow-cytometry. First,
immunohistochemistry measures absolute numbers of cells over a
specific area of tissue, while flow-cytometry measures proportions
of cells within the total isolated cells. Second, flow-cytometry can
define cell subpopulations to a more detailed extent. While the use
of FoxP3 to represent Tregs in immunohistochemistry is logical and
TABLE 3 Multivariate Cox proportional Hazard regression analysis of intratumoral CD8+/FoxP3+ TIL ratio obtained by immunohistochemistry
adjusted for clinicopathologic characteristics
Variables HR 95%CI P-value
Age (per decade increase) 1.33 0.81-2.18 0.264
Gender 0.81 0.28-2.40 0.708
Primary cancer lymph node status 4.80 1.48-15.6 0.009
Time to CRCLM <12 months 0.58 0.21-1.58 0.285
Largest tumor size >5 cm 0.40 0.97-1.64 0.201
>1 metastatic lesion 1.15 0.39-3.36 0.798
CEA >200 ng/mL 10.1 0.99-120 0.051
Margin status (R0 vs R1) 0.82 0.20-3.41 0.786
Intra-tumoral CD8+/FoxP3+ TIL ratio 0.27 0.09-0.81 0.020
For the TIL ratios median values were used as cutoffs.
Bold values signify statistically significant parameters.





Age (per decade increase) 1.64 0.96-2.83 0.073
Gender 0.44 0.14-1.42 0.169
Primary cancer lymph node status 8.09 2.01-32.6 0.003
Time to CRCLM <12 months 0.77 0.28-2.13 0.615
Largest tumor size >5 cm 0.41 0.11-1.44 0.162
>1 metastatic lesion 0.58 0.19-1.83 0.353
CEA >200 ng/mL 45.1 3.88-525 0.002
Margin status (R0 vs R1) 1.14 0.34-5.96 0.637
CD8+/Treg TIL ratio 0.28 0.10-0.84 0.022
For the TIL ratios median values were used as cutoffs.
Bold values signify statistically significant parameters.
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justified,25 this strategy has its limitations. For example, FoxP3 can in
humans, in contrast to mice, also be expressed by activated helper
T-cells.26,27 In addition, activation-induced FoxP3 in human T-
effector cells does not suppress proliferation or cytokine produc-
tion.27 Finally, since flow cytometry uses macroscopically resected
material, it is virtually impossible to exclude the possibility that some
of the peri-tumoral region is present with the tumor sample in some
of the cases. On the other hand the distinction of intra-tumoral
and peri-tumoral compartments can be accurately made with
immunohistochemistry.
No association of immune infiltrate with cancer recurrence was
found. However, overall survival likely reflects the biologic behavior of
colorectal cancer much better than recurrence. While recurrence is
undoubtedly a surrogate of cancer survival, many patients with
recurrence still enjoy long term survival, or cure, due to additional
interventions. A recurrence may not represent aggressive biologic
behavior, but rather metastatic lesions too small to be clinically
detected at the time of initial metastatectomy.
While our study has several strengths it also has limitations. The
main limitation relates to the sample size of our study, stemming from
the need for both prospectively collected flow-cytometric data and
retrospectively collected immunohistochemistry data, in the same
patients. However, despite our sample size, which is comparable to
other similar studies using full slides, and we were able to statistically
confirm our a priori generated hypothesis.
5 | CONCLUSIONS
The ratio of cytotoxic (CD8+) to regulatory (FoxP3+) T-cells, in the
intra-tumoral compartment, but not in the peri-tumoral compartment,
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